190 related articles for article (PubMed ID: 22754588)
1. Risk Factors of Follicular Lymphoma.
Ma S
Expert Opin Med Diagn; 2012 Jul; 6(4):323-333. PubMed ID: 22754588
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors of Non-Hodgkin Lymphoma.
Zhang Y; Dai Y; Zheng T; Ma S
Expert Opin Med Diagn; 2011 Nov; 5(6):539-550. PubMed ID: 22059093
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data.
Albarmawi H; Nagarajan M; Sun K; Gandhi AB; Yared J; Keating KN; Appukkuttan S; Yaldo A; Gharibo M; Onukwugha E
Leuk Lymphoma; 2020 Jan; 61(1):75-83. PubMed ID: 31389296
[TBL] [Abstract][Full Text] [Related]
4. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
5. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
6. An analysis of genetic targets for guiding clinical management of follicular lymphoma.
Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA
Expert Rev Hematol; 2020 Dec; 13(12):1361-1372. PubMed ID: 33176509
[No Abstract] [Full Text] [Related]
7. Follicular lymphomas and their transformation: Past and current research.
Mendez M; Torrente M; Provencio M
Expert Rev Hematol; 2017 Jun; 10(6):515-524. PubMed ID: 28480766
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
Xiao C; Su ZL; Wu QL; Gao HY; Fang JC; Xia ZJ; Guan ZZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):22-7. PubMed ID: 15796877
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
10. Burden of illness of follicular lymphoma and marginal zone lymphoma.
Monga N; Nastoupil L; Garside J; Quigley J; Hudson M; O'Donovan P; Parisi L; Tapprich C; Thieblemont C
Ann Hematol; 2019 Jan; 98(1):175-183. PubMed ID: 30315345
[TBL] [Abstract][Full Text] [Related]
11. T follicular helper cells: a potential therapeutic target in follicular lymphoma.
Ochando J; Braza MS
Oncotarget; 2017 Dec; 8(67):112116-112131. PubMed ID: 29340116
[TBL] [Abstract][Full Text] [Related]
12. Occupational exposure to trichloroethylene and risk of non-Hodgkin lymphoma and its major subtypes: a pooled InterLymph [correction of IinterLlymph] analysis.
Cocco P; Vermeulen R; Flore V; Nonne T; Campagna M; Purdue M; Blair A; Monnereau A; Orsi L; Clavel J; Becker N; de Sanjosé S; Foretova L; Staines A; Maynadié M; Nieters A; Miligi L; 't Mannetje A; Kricker A; Brennan P; Boffetta P; Lan Q; Rothman N
Occup Environ Med; 2013 Nov; 70(11):795-802. PubMed ID: 23881218
[TBL] [Abstract][Full Text] [Related]
13. Transformed follicular lymphoma.
Fischer T; Zing NPC; Chiattone CS; Federico M; Luminari S
Ann Hematol; 2018 Jan; 97(1):17-29. PubMed ID: 29043381
[TBL] [Abstract][Full Text] [Related]
14. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
Hester LL; Park SI; Wood WA; Stürmer T; Brookhart MA; Lund JL
Cancer; 2019 Apr; 125(7):1101-1112. PubMed ID: 30548238
[TBL] [Abstract][Full Text] [Related]
15. Reassessment of non-hodgkins's lymphoma with a "nodular" growth variant: a clinicopathologic study of follicular, mantle cell and marginal zone lymphomas prospectively diagnosed with multiparameter analyses.
Kadowaki I; Ichinohasama R; Sasaki O; Kimura J; Kameoka JI; Meguro K; Endo K; Tobinai K; Sasaki T; Sawai T; Ooya K
Leuk Lymphoma; 1998 Oct; 31(3-4):393-403. PubMed ID: 9869204
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study.
Chang CM; Wang SS; Dave BJ; Jain S; Vasef MA; Weisenburger DD; Cozen W; Davis S; Severson RK; Lynch CF; Rothman N; Cerhan JR; Hartge P; Morton LM
Int J Cancer; 2011 Aug; 129(4):938-47. PubMed ID: 20949561
[TBL] [Abstract][Full Text] [Related]
18. Follicular lymphoma grade 3: review and updates.
Vaidyanathan G; Czuczman MS
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):431-5. PubMed ID: 25066038
[TBL] [Abstract][Full Text] [Related]
19. Identification of predictive pathways for non-hodgkin lymphoma prognosis.
Han X; Li Y; Huang J; Zhang Y; Holford T; Lan Q; Rothman N; Zheng T; Kosorok MR; Ma S
Cancer Inform; 2010 Dec; 9():281-92. PubMed ID: 21245948
[TBL] [Abstract][Full Text] [Related]
20. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lee DH; Kim GW; Kwon SH
Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
